Artiva Biotherapeutics, Inc. (ARTV) News
Follow Artiva Biotherapeutics, Inc. (ARTV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 24 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Artiva Biotherapeutics to Lay Off About 94% of Workforce
Artiva Biotherapeutics is laying off about 94% of its workforce after a drug trial failure and two patient deaths.
EQUITY | Oct 28, 2026, 12:10 AM UTC
M
Artiva Biotherapeutics Shares Fall 31% After AlloNK Development Plan
Artiva Biotherapeutics shares fell 31% after the company announced a plan to end AlloNK development; an analyst also downgraded the shares.
EQUITY | Oct 27, 2026, 06:55 PM UTC
M
Artiva Biotherapeutics Ends AlloNK Program, Shares Slide
Artiva Biotherapeutics pulled the plug on its lead development candidate, AlloNK, and said it would explore alternatives to maximize shareholder value. Shares fell sharply Tuesday.
EQUITY | Oct 27, 2026, 04:48 PM UTC
M
Artiva to Suspend Cell Therapy After Two Patient Deaths, Cut Staff 94%
Artiva will suspend its cell therapy program after two patient deaths and reduce its workforce by 94%.
EQUITY | Oct 27, 2026, 03:10 PM UTC
M
Artiva to End Cell Therapy After Two Patient Deaths, Cut Workforce 94%
Artiva will discontinue its cell therapy program and cut its workforce by 94% after two patient deaths.
EQUITY | Oct 27, 2026, 02:51 PM UTC
M
Artiva Stops Lead Drug Candidate Development After Two Patient Deaths
Artiva Biotherapeutics stopped development of its lead drug candidate after two patient deaths during a clinical trial. ARTV shares fell 32%, heading for their worst session since April 2025.
EQUITY | Oct 27, 2026, 02:09 PM UTC
M
Artiva Shares Fall 30% as Company Discontinues Cell Therapy, Cuts Workforce 94%
Artiva Biotherapeutics discontinued its cell therapy after two patient deaths and cut its workforce by 94%.
EQUITY | Oct 27, 2026, 01:35 PM UTC
M
Artiva Halts Cell Therapy After Two Patient Deaths, Cuts Workforce 94%
Artiva Biotherapeutics said it would halt development of its experimental cell therapy for certain autoimmune conditions after two deaths among patients being tested on the treatment. Its shares fell 30% in premarket tra
EQUITY | Oct 27, 2026, 12:21 PM UTC
M
Artiva Biotherapeutics to Cut Workforce by About 94%
Artiva Biotherapeutics is reducing its workforce by about 94% and evaluating strategic alternatives.
EQUITY | Oct 27, 2026, 12:01 PM UTC
M
Artiva Halts AlloNK Development After Safety Events
Artiva halted AlloNK development after safety events and insufficient response durability.
EQUITY | Oct 27, 2026, 11:35 AM UTC
M
Artiva Biotherapeutics Discontinues AlloNK Development
Artiva Biotherapeutics is halting further development of AlloNK (AB-101), including the planned Phase 3 pivotal trial.
EQUITY | Oct 27, 2026, 11:31 AM UTC
L
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-upSAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva
NEWS | Sep 23, 2026, 11:33 AM UTC
L
ARTV - Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
ARTV - Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
NEWS | Sep 23, 2026, 11:30 AM UTC
L
ARTV - Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
ARTV - Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
NEWS | Sep 17, 2026, 12:00 PM UTC
L
ARTV: Allogeneic NK cell therapy for refractory RA shows strong efficacy and advances to phase III
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing deep B-cell depletion and strong efficacy in early trials. Phase III is underway with robust funding, rapid community-based enrollm
NEWS | Sep 14, 2026, 07:38 PM UTC
L
ARTV: Allogeneic NK cell therapy for refractory RA shows strong efficacy, safety, and broad potential
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing strong efficacy and safety, with a pivotal phase III trial underway and broad expansion potential. Key milestones include updated c
NEWS | Sep 14, 2026, 07:15 PM UTC
L
ARTV advances pivotal Phase III trial in refractory RA
A novel NK cell platform is advancing in autoimmune disease with a pivotal Phase III trial in refractory RA targeting deep B-cell depletion, citing promising early efficacy and safety.
EQUITY | Sep 09, 2026, 04:05 PM UTC
M
ARTV advances pivotal Phase III trial for refractory RA
ARTV’s AlloNK cell platform is advancing in a pivotal Phase III trial for refractory RA. Enrollment is robust, with data updates expected by year-end and top-line results targeted for 2028.
EQUITY | Sep 09, 2026, 03:29 PM UTC
L
Artiva Biotherapeutics updates planned Allonk data and 2026 milestones
Artiva Biotherapeutics Inc provided an update on planned Allonk data disclosures and development milestones for the remainder of 2026.
EQUITY | Sep 08, 2026, 11:47 AM UTC
L
ARTV - Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 - Cli
ARTV - Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
EQUITY | Sep 08, 2026, 11:30 AM UTC
L
Artiva Biotherapeutics CEO Aslan Fred sells $690K in shares
Aslan Fred, a director and Chief Executive Officer, sold 61,888 shares in an automatic sell-to-cover under a reported Form 4 filing. Weighted average sale price was $11.1555 per share, totaling $690,391.
EQUITY | Sep 04, 2026, 08:12 PM UTC
L
Artiva Biotherapeutics to participate in September investor conferences
Artiva Biotherapeutics announced management will participate in upcoming investor conferences in September.
EQUITY | Sep 02, 2026, 12:37 PM UTC
L
ARTV - Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
ARTV - Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
EQUITY | Sep 02, 2026, 12:30 PM UTC
M
Insiders Buy HDSN, XAIR, ARTV, IONS Shares
Insiders purchase shares of four companies
EQUITY | Aug 03, 2026, 09:28 AM UTC